非小细胞肺癌抗PD-1/PD-L1治疗研究进展

摘要

The current clinical intervention for lung cancer is relatively small, mainly including surgery, radiotherapy, chemical therapy treatment. Therefore, the poor prognosis of patients with advanced lung cancer. In recent years, gradually began to implement the immune therapy, it has gradually become the focus of the current study. Programmed cell death 1 (PD-1) / programmed cell death 1 ligand (PD-L1) in the occurrence and development of tumors is the main immune checkpoint, to prove the existence of correlation between survival the anti PD-1 monoclonal antibody and inhibitor in patients with advanced non-small cell lung cancer, and PD-L1 as a biological marker, can effectively predict effcacy. Research progress in the implementation of anti PD-1/PD-L1 therapy for non-small cell lung cancer mainly analyzed in this paper.%当前临床对于肺癌的干预手段比较少，主要包括手术、放疗、化疗。因此，晚期肺癌患者预后不佳。近些年逐渐开始实施免疫治疗，这也逐渐成为当前研究的重点。程序性死亡分子1（PD-1）/程序性死亡分子1配体（PD-L1）在肿瘤的发生及发展中是主要的免疫检查点，证明其抑制剂抗PD-1单抗与非小细胞肺癌晚期患者的生存情况存在明显关联，另外PD-L1作为一种生物标记物，能够有效进行疗效预测。本文主要分析对非小细胞肺癌实施抗PD-1/PD-L1治疗的研究进展。